A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment

Trial Profile

A Randomized, Double-masked, Placebo-controlled Study of the Safety and Efficacy of Gevokizumab in the Treatment of Subjects With Non-infectious Intermediate, Posterior, or Pan-uveitis Currently Controlled With Systemic Treatment

Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Behcet's syndrome; Uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms Estudio EYEGUARD-C; EYEGUARD-C
  • Sponsors XOMA
  • Most Recent Events

    • 15 Oct 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
    • 18 Feb 2015 Planned End Date changed from 1 Feb 2015 to 1 Apr 2015 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top